Tirzepatide before and after: what the trials actually show

Last updated 2026-07-30

What does a tirzepatide before and after actually measure?

A tirzepatide before and after usually means two numbers: body weight (or A1C for diabetes) at the start of treatment, and the same measurement after a set number of weeks, most often 36, 52, or 72 weeks because that's how the main trials were structured. Photos are the marketing version of this. The trial data is the real version, and it's less flattering because it includes everyone, more than people who stuck with it and responded well. The FDA approved tirzepatide under two brand names: Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for chronic weight management (approved November 2023) ^[1][2]. Both are the same molecule, dosed the same way, but studied in different populations and marketed for different indications. Compounded tirzepatide, sold by compounding pharmacies during the FDA shortage period, is not FDA-approved as a product, even though the base drug it's made from comes from a different source than the branded versions. When you see a before/after claim online, ask three questions: what dose, what week, and what population (diabetic or not, since results differ). Most viral transformation photos don't answer any of these.

How much weight do people lose on tirzepatide, according to the trials?

The headline numbers come from SURMOUNT-1 (NCT04184622), a 72-week, phase 3 trial in 2,539 adults with obesity or overweight without type 2 diabetes. Average weight loss was 15.0% on the 5 mg dose, 19.5% on 10 mg, and 20.9% on 15 mg, compared to 3.1% on placebo ^[3]. Those are mean values. A meaningful chunk of participants did much better: 57% of people on 10 mg and 63% on 15 mg lost at least 20% of their body weight, according to the published New England Journal of Medicine results ^[3]. SURMOUNT-2 (NCT04657003) tested tirzepatide in people who also had type 2 diabetes, a population that historically loses less weight on any GLP-1 therapy. Over 72 weeks, average loss was 12.8% on 10 mg and 14.7% on 15 mg, versus 3.2% on placebo ^[4]. That gap between diabetic and non-diabetic responders is one of the most consistent findings across the whole GLP-1/GIP class, not unique to tirzepatide. For a sense of the individual spread rather than just the average, see our tirzepatide success rate breakdown, which covers what percentage of people hit 5%, 10%, 15%, and 20%+ thresholds.

What does a tirzepatide before and after look like month by month?

Weight loss on tirzepatide is not linear and it's not fast in month one. Most people notice appetite suppression within the first 1 to 2 weeks, but visible weight change usually shows up around week 4 to 6, once the dose has been titrated up from the 2.5 mg starting dose. In SURMOUNT-1, the dose was titrated over 20 weeks, increasing every 4 weeks (2.5, 5, 7.5, 10, 12.5, up to 15 mg), specifically to reduce GI side effects ^[3]. That means the biggest weight changes tend to cluster in months 3 through 9, as people reach and hold their target dose. By week 72, the curve was still trending downward for many people rather than plateauing, according to the trial's weight-loss trajectory data ^[3]. For a week-by-week narrative version of this, our tirzepatide first month what to expect piece covers the early titration phase specifically, and tirzepatide results timeline maps out the longer arc through a full year.

How does tirzepatide's A1C effect compare in people with type 2 diabetes?

For type 2 diabetes, the SURPASS program is the reference point, not SURMOUNT. SURPASS-2 (NCT03987919) compared tirzepatide directly against semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks. Tirzepatide at 15 mg lowered A1C by 2.30 percentage points versus 1.86 for semaglutide, and produced greater weight loss too (11.2 kg vs 5.7 kg) ^[5]. Across the wider SURPASS program, A1C reductions of roughly 1.8 to 2.1 percentage points are typical depending on dose and baseline A1C, per the FDA-reviewed Mounjaro prescribing information ^[1]. That's a meaningfully large drop. For context, many older oral diabetes drugs lower A1C by 0.5 to 1.0 points. This is part of why the FDA's Mounjaro label calls it an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes ^[1], not a weight-loss product, even though weight loss was a consistent secondary finding across every SURPASS trial.

Do before and after photos overstate the real results?

Yes, in a specific and predictable way: survivorship bias. The person posting a 6-month transformation photo is, by definition, someone who tolerated the drug well enough to keep taking it and responded well enough to want to show off the result. Trial dropout data tells a different story. In SURMOUNT-1, discontinuation due to adverse events occurred in 4.3% to 7.1% of tirzepatide groups depending on dose, versus 2.6% on placebo ^[3]. Those people aren't in anyone's before/after post. Photos also hide dose. Someone at 15 mg for 72 weeks and someone at 5 mg for 12 weeks look completely different, but both get posted as generic tirzepatide results. And photos hide plateau and regain. A tirzepatide withdrawal study (SURMOUNT-4, NCT04660643) found that participants who stopped the drug after 36 weeks and switched to placebo regained an average of 14 percentage points of the weight they'd lost over the following 52 weeks, while those who stayed on tirzepatide continued to lose a bit more ^[6]. Nobody posts the regain photo. For a more skeptical read on how individual results vary, tirzepatide reviews collects patterns across real patient reports rather than curated transformation content.

What are the real side effects behind the before and after numbers?

The dominant side effects are gastrointestinal, and they're common, not rare. In SURMOUNT-1, nausea occurred in roughly 24% to 33% of participants across dose groups, diarrhea in about 17% to 23%, and vomiting in 8% to 12%, mostly during dose escalation ^[3]. These generally taper as the body adjusts to a stable dose, which is exactly why the titration schedule exists. Beyond the common stuff, tirzepatide carries a boxed warning for thyroid C-cell tumors, based on findings in rodent studies. The FDA label states tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1][2]. Whether this translates to human risk is unresolved; it's a rodent-model signal that triggered a precautionary warning, and the label reflects that caution rather than confirmed human incidence. Other signals worth knowing before you start: acute pancreatitis has been reported in clinical trials, gallbladder-related disorders including cholelithiasis occurred more often on tirzepatide than placebo, and severe GI reactions can worsen diabetic retinopathy risk indirectly through rapid glycemic change ^[1][2]. None of these show up in a before/after photo, but they're part of the real risk profile anyone comparing this drug against a picture on Instagram should weigh. For the fuller tradeoff discussion, see tirzepatide pros and cons.

How does tirzepatide's before and after compare to semaglutide (Wegovy/Ozempic)?

Head-to-head data (more than cross-trial comparison) comes from SURMOUNT-5 (NCT05822830), which directly compared tirzepatide to semaglutide for weight loss, and from SURPASS-2 for diabetes. In SURMOUNT-5, tirzepatide produced significantly greater weight loss than semaglutide over 72 weeks in adults with obesity, according to the trial's topline results released by Eli Lilly . In SURPASS-2, tirzepatide 15 mg outperformed semaglutide 1 mg on both A1C (2.30 vs 1.86 point reduction) and weight (11.2 kg vs 5.7 kg) over 40 weeks ^[5]. | Trial | Population | Comparator | Tirzepatide result | Comparator result |

Does tirzepatide before and after differ for men versus women, or by starting weight?

Trial subgroup analyses show weight loss percentage is fairly consistent across sex, but starting BMI matters. In practical terms, people starting at a higher BMI often lose more total pounds but a similar or slightly smaller percentage of body weight compared to people starting closer to the overweight threshold, a pattern seen across most GLP-1/GIP obesity trials including SURMOUNT-1 ^[3]. Age and baseline A1C (in diabetic populations) also shift the numbers: people with higher starting A1C tend to see larger absolute A1C drops, simply because there's more room to fall, a pattern documented across the SURPASS program ^[5]. None of the major trials found a clean sex-based difference in percentage weight loss large enough to change dosing guidance. If your own before/after doesn't match the trial average in a specific direction, dose, adherence to the titration schedule, diet during treatment, and individual metabolic response explain far more of the variance than sex or age alone.

What happens to the before and after result if you stop tirzepatide?

It largely reverses. SURMOUNT-4 randomized participants who'd completed 36 weeks of tirzepatide (reaching maintenance dose) to either continue the drug or switch to placebo for another 52 weeks. The continuation group lost an additional 5.5% of body weight on average. The placebo-switch group regained 14 percentage points of body weight (a rebound of most, though not all, of what they'd lost) ^[6]. This is the single most important fact missing from every viral before/after post: it's a snapshot, not an endpoint. Tirzepatide, like other GLP-1/GIP drugs, is currently studied and prescribed as a long-term, ongoing therapy for chronic weight management, similar in structure to how blood pressure medication works. Stopping it doesn't preserve the result for most people. If long-term commitment (and cost) wasn't part of your before/after math, it needs to be. Our is tirzepatide worth it piece runs the actual cost-benefit numbers on that question.

How should I read a tirzepatide before and after I see online?

Treat it as one anecdote, not data. Useful things to check: what dose and for how long, whether the person disclosed side effects or dropout risk, and whether it's a compounded or branded product (compounded tirzepatide isn't FDA-reviewed for safety or efficacy the way Zepbound and Mounjaro are, since it's typically made under pharmacy compounding provisions rather than the New Drug Application pathway the FDA used to approve the branded versions ^[1][2]). A transformation photo also can't show you A1C, blood pressure, lipid panel, or gallbladder ultrasound results, all of which the actual trials tracked and which matter more for long-term health than how someone looks in a t-shirt. If you're building your own expectations, the trial averages (15% to 20.9% weight loss over 72 weeks for non-diabetics, 1.8 to 2.3 point A1C drops for diabetics) are a far more honest starting point than any single photo, curated or not. If you're weighing whether to start, working with a provider who reviews your labs, thyroid history, and GI history before prescribing (rather than a site that just sells you a vial) is the difference between informed and lucky. Tirz Rx's provider-reviewed model, fulfilled through its pharmacy partner, is built around that screening step rather than skipping it.

Frequently asked questions

How much weight can you realistically lose on tirzepatide?

Trial averages from SURMOUNT-1 show 15.0% loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks in adults without diabetes, versus 3.1% on placebo. People with type 2 diabetes typically lose somewhat less, around 12.8% to 14.7% in SURMOUNT-2. Individual results vary widely around these averages.

How long does it take to see before and after results on tirzepatide?

Appetite changes often start within 1 to 2 weeks. Visible weight change usually shows up by week 4 to 6. Because dosing is titrated up over roughly 20 weeks to limit GI side effects, the largest changes typically happen between months 3 and 9, with continued loss often through week 72 in trial data.

Does tirzepatide work differently for people with type 2 diabetes versus those without?

Yes. People with type 2 diabetes generally lose a smaller percentage of body weight on the same dose compared to people without diabetes, a pattern seen consistently across GLP-1/GIP trials. SURMOUNT-2 (diabetic population) showed 12.8-14.7% loss versus SURMOUNT-1's 15.0-20.9% (non-diabetic), both at 72 weeks.

What happens if you stop taking tirzepatide after seeing good results?

Most people regain a substantial portion of the weight. SURMOUNT-4 found participants switched to placebo after 36 weeks regained 14 percentage points of body weight over the next year, while those who continued tirzepatide lost an additional 5.5%. It's designed as an ongoing therapy, not a short course.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

The active drug is chemically identical, but compounded tirzepatide is not FDA-approved as a finished product the way Mounjaro (for type 2 diabetes) and Zepbound (for weight management) are. Compounded versions are made under pharmacy compounding rules, generally without the same product-level FDA review of manufacturing consistency and efficacy.

What are the most common side effects shown in tirzepatide trials?

Gastrointestinal issues dominate: nausea in roughly 24-33% of participants, diarrhea in 17-23%, and vomiting in 8-12% across SURMOUNT-1 dose groups, mostly during dose titration. These typically ease once a stable maintenance dose is reached.

Does tirzepatide cause thyroid cancer?

Human risk is unconfirmed. The FDA boxed warning is based on thyroid C-cell tumors seen in rodent studies, and tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Whether this rodent signal applies to humans remains unresolved in current data.

How does tirzepatide compare to semaglutide for weight loss?

In SURPASS-2, tirzepatide 15 mg produced greater A1C reduction (2.30 vs 1.86 points) and weight loss (11.2 kg vs 5.7 kg) than semaglutide 1 mg over 40 weeks in diabetic adults. SURMOUNT-5 found tirzepatide produced significantly more weight loss than semaglutide in adults with obesity over 72 weeks.

Why do some before and after photos look more dramatic than trial averages?

Survivorship bias. People who post transformation photos tolerated the drug well enough to stay on it and got a good result, so they're not representative of everyone who started. Trial dropout rates of 4.3% to 7.1% due to side effects in SURMOUNT-1 show a meaningful share of people never reach a dramatic before/after.

What dose of tirzepatide produces the best before and after results?

Higher doses correlate with more weight loss in trials: 15 mg produced 20.9% average loss versus 15.0% at 5 mg in SURMOUNT-1. But higher doses also carry more GI side effects, which is why dosing is titrated slowly starting at 2.5 mg rather than jumping straight to a high dose.

Can you tell someone's tirzepatide dose from their before and after photo?

No. Photos don't disclose dose, duration, diet changes, or exercise habits, all of which affect the result as much as or more than the drug itself. Two people on very different doses and timelines can post visually similar transformation photos.

Does tirzepatide affect blood pressure and cholesterol, more than weight?

Trials report secondary improvements in some cardiometabolic markers alongside weight loss, though these aren't the primary endpoint of SURMOUNT or SURPASS trials and photos never show them. A full lab panel before and during treatment, more than a scale number, is the more complete way to track response.

Sources

1. FDA, Mounjaro (tirzepatide) prescribing information: Boxed warning for thyroid C-cell tumors, contraindication in MTC/MEN 2, approval as adjunct to diet and exercise for type 2 diabetes
2. FDA, Zepbound (tirzepatide) prescribing information: FDA approval of Zepbound for chronic weight management, November 2023, boxed warning and MTC/MEN 2 contraindication
3. Jastreboff AM, et al., New England Journal of Medicine (SURMOUNT-1): 72-week weight loss results of 15.0-20.9% on tirzepatide vs 3.1% on placebo, plus GI adverse event rates and discontinuation data
4. ClinicalTrials.gov, SURMOUNT-1 (NCT04184622): Trial identifier and design for SURMOUNT-1
5. ClinicalTrials.gov, SURMOUNT-2 (NCT04657003): Trial identifier for SURMOUNT-2 in adults with type 2 diabetes
6. Frias JP, et al., New England Journal of Medicine (SURPASS-2): Head-to-head comparison of tirzepatide 15 mg vs semaglutide 1 mg on A1C and weight change at 40 weeks
7. ClinicalTrials.gov, SURPASS-2 (NCT03987919): Trial identifier for SURPASS-2
8. ClinicalTrials.gov, SURMOUNT-4 (NCT04660643): Trial identifier for SURMOUNT-4 withdrawal/continuation design
9. ClinicalTrials.gov, SURMOUNT-5 (NCT05822830): Trial identifier for SURMOUNT-5 head-to-head tirzepatide vs semaglutide weight loss comparison